Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or … (NCT07386704) | Clinical Trial Compass
By InvitationPhase 2
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
China30 participantsStarted 2025-12-09
Plain-language summary
This study is a prospective, single-arm trial, aiming to enroll 30 patients with unresectable locally advanced or oligometastatic pancreatic cancer. The study will evaluate the efficacy and safety of nintedanib combined with radiotherapy and chemotherapy (gemcitabine or capecitabine monotherapy). The primary endpoint of this study is the 1-year local control rate (LCR).
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Confirmed by histological or cytological examination as pancreatic adenocarcinoma;
✓. Confirmed by imaging as locally advanced or oligometastatic (number of metastatic lesions ≤ 3);
✓. Evaluated by the clinical doctor as inoperable or the patient refuses surgery;
✓. ECOG PS score 0-1;
✓. No radiotherapy has been performed on the upper abdomen before, and no any palliative chemotherapy or other systemic anti-tumor treatment has been received;
✓. According to the RECIST 1.1 evaluation criteria, there are measurable lesions;
✓. Sufficient organ and bone marrow functions
Exclusion criteria
✕. Previous history of abdominal radiotherapy.
✕. Those with a history of other malignant tumors (excluding cured skin basal cell carcinoma and cervical carcinoma in situ).
✕. Those allergic to the drugs or their components used in this protocol.
✕. Those with known HIV or syphilis infection, or currently in the active stage of hepatitis (hepatitis B or hepatitis C).
✕. Those who have undergone major surgery within 30 days before screening.
✕
What they're measuring
1
LCR
Timeframe: The 1-year local control rate (LCR) of patients receiving nivolumab combined with radiotherapy and chemotherapy